Skip to content

META English logo

Main menu
    • About us
      • Vision, mission and values
      • Diversity, equity & inclusion
      • Executive Leadership Team
      • Global Leaders
      • Board of Directors
      • Our leaders
    • Environmental, social & governance
    • Policies & positions
    • Suppliers
    • Media
    • Press releases
    • Women’s Health Accelerator
    • Rahet Bally x Organon
    • Investor relations overview
    • SEC filings
  • Join our team

Contact Us

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:
Our people

Aspiring to help shape the fertility journey of the modern family

November 3, 2021

Share this article

Elisabeth Weis
Elisabeth Weis
Associate Vice President, Global Commercial Lead, Fertility

Spending time with my two adorable grandsons reminds me of the joy that couples, women, and other family members aspire to feel at the beginning of a fertility journey, as they imagine the reality of building a family. This time together also reminds me of the emotional and physical aspects of the journey that hopeful parents to be must navigate together. While the boys can’t join me on the job, their constant presence in my mind motivates me in my work every day: leading a team of people who aim to help others who experience infertility, an increasing problem for women and men around the world.

People living with infertility may feel alone and isolated in their experience. They very often face difficult
decisions along the way. During treatment, they may receive overwhelming amounts of information
about treatment choices and costs, while experiencing emotional and physical aspects of the journey.

I strongly believe that every couple and aspiring single parent, who is looking to start a family, should be offered support on their path, and I’m proud to work for a company that is committed to listening to understand what is important to aspiring parents on this journey. It is especially valuable for me to learn more about today’s modern family, which includes heterosexual couples, gay couples, and single parents. At Organon, we aspire to work with a broad range of healthcare providers including nurses and reproductive endocrinologists, advocacy groups, treatment centers, and others to provide women and men with relevant quality information to enable an informed dialogue about what the fertility journey entails. At the same time, we appreciate that the aspiring couple or single parent is mostly accompanied on their journey by so many others, beyond the care team, including family, friends, and other loved ones, and of course we need to acknowledge them, as well.

At Organon, our aspiration is to help people, who may be on the journey alone, seeking fertility treatment by focusing on these key areas:

  • Working with advocacy organizations, individual healthcare providers, and treatment centers to learn more about unmet needs and collaborate on creating educational resources future parents can use through every step of the fertility journey
  • Championing care equity by increasing access to our treatments as we work to reach more couples and women around the world
  • Collaborating with clinics and research institutions to drive innovation and solutions that meet the diverse needs of women and men
  • Elevating fertility education, with the goal of increasing awareness of treatment options and providing resources to help future parents along their fertility journey, including how to talk to their care teams and loved ones
  • And, of course, investment in our current fertility products and future opportunities to broaden our portfolio and identify new treatments, diagnostics, and devices built around patient needs

I’ll be the first to say that we don’t have all the answers. But as I think about my grandsons, and the joy that may seem out of reach to so many people, I am determined, with my team, to help navigate the fertility journey for others. We are passionate about what we do and we will continue to listen and
strive to help address the needs of future parents all over the world.

META English logo

Company

  • About us
  • Our leaders
  • Environmental, social & governance

Resources

  • Patient resources
  • Investor relations
  • Media

Contact us

  • Contact Us
  • Contact information
  • Global locations
  • Forward-Looking Statement
  • cookie policy
  • Privacy
  • Terms of Use
  • Sitemap
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept